Styrylquinazoline derivatives as ABL inhibitors selective for different DFG orientations

References

• Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol. 2008;15(10):1109–1118.
   PubMed Web of Science ®Google Scholar
• Skora L, Mestan J, Fabbro D, Jahnke W, Grzesiek S. Nmr reveals the allosteric opening and closing of abelson tyrosine kinase by atp-site and myristoyl pocket inhibitors. Proc Natl Acad Sci USA. 2013;110(47):E4437–4445.
   PubMed Web of Science ®Google Scholar
• Chen S, Dumitrescu TP, Smithgall TE, Engen JR. Abl n-terminal cap stabilization of sh3 domain dynamics. Biochemistry. 2008;47(21):5795–5803.
   PubMed Web of Science ®Google Scholar
• Panjarian S, Iacob RE, Chen S, Engen JR, Smithgall TE. Structure and dynamic regulation of abl kinases. J Biol Chem. 2013;288(8):5443–5450.
   PubMed Web of Science ®Google Scholar
• Gray NS, Fabbro D. Discovery of allosteric bcr-abl inhibitors from phenotypic screen to clinical candidate. Methods Enzymol. 2014;548:173–188.
   PubMed Web of Science ®Google Scholar
• Fabbro D, Manley PW, Jahnke W, Liebetanz J, Szyttenholm A, Fendrich G, Strauss A, Zhang J, Gray NS, Adrian F, et al. Inhibitors of the abl kinase directed at either the ATP- or myristate-binding site. Biochim Biophys Acta. 2010;1804(3):454–462.
   PubMed Web of Science ®Google Scholar
• Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob SW, Dodd S, Drueckes P, Fabbro D, Gabriel T, et al. Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J Med Chem. 2018;61(18):8120–8135.
   PubMed Web of Science ®Google Scholar
• Cowan-Jacob SW, Fendrich G, Manley PW, Jahnke W, Fabbro D, Liebetanz J, Meyer T. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure. 2005;13(6):861–871.
   PubMed Web of Science ®Google Scholar
• Atwell S, Adams JM, Badger J, Buchanan MD, Feil IK, Froning KJ, Gao X, Hendle J, Keegan K, Leon BC, et al. A novel mode of gleevec binding is revealed by the structure of spleen tyrosine kinase. J Biol Chem. 2004;279(53):55827–55832.
   PubMed Web of Science ®Google Scholar
• Vijayan RS, He P, Modi V, Duong-Ly KC, Ma H, Peterson JR, Dunbrack RL, Jr., Levy RM. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type ii inhibitors. J Med Chem. 2015;58(1):466–479.
   PubMed Web of Science ®Google Scholar
• Hanson SM, Georghiou G, Thakur MK, Miller WT, Rest JS, Chodera JD, Seeliger MA. What makes a kinase promiscuous for inhibitors? Cell Chem Biol. 2019;26(3):390–399 e395.
   PubMed Web of Science ®Google Scholar
• Mularski J, Malarz K, Pacholczyk M, Musiol R. The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series. Eur J Med Chem. 2019;163:610–625.
   PubMed Web of Science ®Google Scholar
• Hantschel O, Nagar B, Guettler S, Kretzschmar J, Dorey K, Kuriyan J, Superti-Furga G. A myristoyl/phosphotyrosine switch regulates c-ABL. Cell. 2003;112(6):845–857.
   PubMed Web of Science ®Google Scholar
• McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of bcr is essential for the transforming function of BCR-ABL oncoproteins. Mol Cell Biol. 1993;13(12):7587–7595.
   PubMed Web of Science ®Google Scholar
• Mian AA, Metodieva A, Badura S, Khateb M, Ruimi N, Najajreh Y, Ottmann OG, Mahajna J, Ruthardt M. Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I. BMC Cancer. 2012;12:411.
   PubMed Web of Science ®Google Scholar
• Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, Schultz AR, Clair P, Bowler AD, Pomicter AD, et al. Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell. 2019;36(4):431–443 e435.
   PubMed Web of Science ®Google Scholar
• Zhang J, Adrian FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE, Sim T, Powers J, Dierks C, Sun F, et al. Targeting BCR-ABL by combining allosteric with atp-binding-site inhibitors. Nature. 2010;463(7280):501–506.
   PubMed Web of Science ®Google Scholar
• Mrozek-Wilczkiewicz A, Malarz K, Rejmund M, Polanski J, Musiol R. Anticancer activity of the thiosemicarbazones that are based on di-2-pyridine ketone and quinoline moiety. Eur J Med Chem. 2019;171:180–194.
   PubMed Web of Science ®Google Scholar
• Mrozek-Wilczkiewicz A, Kuczak M, Malarz K, Cieślik W, Spaczyńska E, Musiol R. The synthesis and anticancer activity of 2-styrylquinoline derivatives. A p53 independent mechanism of action. Eur J Med Chem. 2019;177:338–349.
   PubMed Web of Science ®Google Scholar
• Mrozek-Wilczkiewicz A, Spaczynska E, Malarz K, Cieslik W, Rams-Baron M, Krystof V, Musiol R. Design, synthesis and in vitro activity of anticancer styrylquinolines. The p53 independent mechanism of action. PLoS One. 2015;10(11):e0142678.
   PubMed Web of Science ®Google Scholar
• Jampilek J, Musiol R, Finster J, Pesko M, Carroll J, Kralova K, Vejsova M, O'Mahony J, Coffey A, Dohnal J, et al. Investigating biological activity spectrum for novel styrylquinazoline analogues. Molecules. 2009;14(10):4246–4265.
   PubMed Web of Science ®Google Scholar
• Malarz K, Mularski J, Kuczak M, Mrozek-Wilczkiewicz A, Musiol R. Novel benzenesulfonate scaffolds with a high anticancer activity and g2/m cell cycle arrest. Cancers (Basel). 2021;13(8):1790.
   PubMed Web of Science ®Google Scholar
• Lewis AK, Dunleavy KM, Senkow TL, Her C, Horn BT, Jersett MA, Mahling R, Mccarthy MR, Perell GT, Valley CC, et al. Oxidation increases the strength of the methionine-aromatic interaction. Nat Chem Biol. 2016;12(10):860–866.
   PubMed Web of Science ®Google Scholar
• Kim SH, Bajji A, Tangallapally R, Markovitz B, Trovato R, Shenderovich M, Baichwal V, Bartel P, Cimbora D, McKinnon R, et al. Discovery of (2s)-1-[4-(2-6-amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9h-purin-9-ylethyl)piperidin-1-yl]-2-hydroxypropan-1-one (mpc-3100), a purine-based hsp90 inhibitor. J Med Chem. 2012;55(17):7480–7501.
   PubMed Web of Science ®Google Scholar
• Geoghegan K, Smullen S, Evans P. Halonium ion triggered rearrangement of unsaturated benzo-annulated bi- and tricyclic sulfonamides. J Org Chem. 2013;78(20):10443–10451.
   PubMed Web of Science ®Google Scholar
• Bellale EV, Chaudhari MK, Akamanchi KG. A simple, fast and chemoselective method for the preparation of arylthiols. Synthesis-Stuttgart. 2009;2009(19):3211–3213.
   Google Scholar
• Badwan A. Benzene sulfonamides as pde-v inhibitors for the use against erectile dysfunction. In: Benzene sulfonamides as pde-v inhibitors for the use against erectile dysfunction. Omm Al-Amad: Jordanian Pharmaceutical Manufacturing and Medical Equipment Co.; 2000.
   Google Scholar
• Bardelle C, Cross D, Davenport S, Kettle JG, Ko EJ, Leach AG, Mortlock A, Read J, Roberts NJ, Robins P, et al. Inhibitors of the tyrosine kinase EphB4. Part 1: structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines. Bioorg Med Chem Lett. 2008;18(9):2776–2780.
   PubMed Web of Science ®Google Scholar
• Youssif BGM, Gouda AM, Moustafa AH, Abdelhamid AA, Gomaa HAM, Kamal I, Marzouk AA. Design and synthesis of new triarylimidazole derivatives as dual inhibitors of BRAFv600e/p38α with potential antiproliferative activity. J Mol Struct . 2022;1253:132218.
   Web of Science ®Google Scholar
• Xie T, Saleh T, Rossi P, Kalodimos CG. Conformational states dynamically populated by a kinase determine its function. Science. 2020;370(6513):eabc2754.
   PubMed Web of Science ®Google Scholar
• Laurini E, Posocco P, Fermeglia M, Gibbons DL, Quintas-Cardama A, Pricl S. Through the open door: preferential binding of dasatinib to the active form of BCR-ABL unveiled by in silico experiments. Mol Oncol. 2013;7(5):968–975.
   PubMed Web of Science ®Google Scholar
• Grzesiek S, Paladini J, Habazettl J, Sonti R. Imatinib disassembles the regulatory core of abelson kinase by binding to its atp site and not by binding to its myristoyl pocket. Magn Reson. 2022;3(1):91–99.
   Google Scholar
• Johnson TK, Bochar DA, Vandecan NM, Furtado J, Agius MP, Phadke S, Soellner MB. Synergy and antagonism between allosteric and active-site inhibitors of ABL tyrosine kinase. Angew Chem Int Ed Engl. 2021;60(37):20196–20199.
   PubMed Web of Science ®Google Scholar
• Vogtherr M, Saxena K, Hoelder S, Grimme S, Betz M, Schieborr U, Pescatore B, Robin M, Delarbre L, Langer T, et al. Nmr characterization of kinase p38 dynamics in free and ligand-bound forms. Angew Chem Int Ed Engl. 2006;45(6):993–997.
   PubMed Web of Science ®Google Scholar
• Niedbała M, Malarz K, Sharma G, Kramer-Marek G, Kaspera W. Glioblastoma: pitfalls and opportunities of immunotherapeutic combinations. Onco Targets Ther. 2022;15:437–468.
   PubMed Web of Science ®Google Scholar
• Malarz K, Mularski J, Pacholczyk M, Musiol R. The landscape of the anti-kinase activity of the IDH1 inhibitors. Cancers. 2020;12(3):536.
   PubMed Web of Science ®Google Scholar
• Amarante-Mendes GP, Rana A, Datoguia TS, Hamerschlak N, Brumatti G. BCR-ABL1 tyrosine kinase complex signaling transduction: challenges to overcome resistance in chronic myeloid leukemia. Pharmaceutics. 2022;14(1):215.
   PubMed Web of Science ®Google Scholar
• Khoo KH, Verma CS, Lane DP. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov. 2014;13(3):217–236.
   PubMed Web of Science ®Google Scholar
• Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. Tp53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007;26(15):2157–2165.
   PubMed Web of Science ®Google Scholar
• Morotti A, Carra G, Crivellaro S. The p53 orbit in chronic myeloid leukemia: time to move to patient care. Transl Cancer Res. 2016;5(S6):S1288–S1291.
   Google Scholar
• Udden SM, Morita-Fujimura Y, Satake M, Ikawa S. c-ABL tyrosine kinase modulates p53-dependent p21 induction and ensuing cell fate decision in response to DNA damage. Cell Signal. 2014;26(2):444–452.
   PubMed Web of Science ®Google Scholar
• Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, Fujii S, Arlinghaus RB, Czerniak BA, Sen S. Phosphorylation by aurora kinase a induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet. 2004;36(1):55–62.
   PubMed Web of Science ®Google Scholar
• Furlan A, Stagni V, Hussain A, Richelme S, Conti F, Prodosmo A, Destro A, Roncalli M, Barila D, Maina F. ABL interconnects oncogenic met and p53 core pathways in cancer cells. Cell Death Differ. 2011;18(10):1608–1616.
   PubMed Web of Science ®Google Scholar
• Wendel H-G, de Stanchina E, Cepero E, Ray S, Emig M, Fridman JS, Veach DR, Bornmann WG, Clarkson B, McCombie WR, et al. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci U S A. 2006;103(19):7444–7449.
   PubMed Web of Science ®Google Scholar
• Thottassery JV, Westbrook L, Someya H, Parker WB. C-abl-independent p73 stabilization during gemcitabine- or 4'-thio-beta-d-arabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells. Mol Cancer Ther. 2006;5(2):400–410.
   PubMed Web of Science ®Google Scholar
• Higuchi M, Ishiyama K, Maruoka M, Kanamori R, Takaori-Kondo A, Watanabe N. Paradoxical activation of c-Src as a drug-resistant mechanism. Cell Rep. 2021;34(12):108876.
   PubMed Web of Science ®Google Scholar
• Eifert C, Wang X, Kokabee L, Kourtidis A, Jain R, Gerdes MJ, Conklin DS. A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis. Genes Chromosomes Cancer. 2013;52(10):961–975.
   PubMed Web of Science ®Google Scholar
• Colicelli J. ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci Signal. 2010;3(139):re6.
   PubMed Web of Science ®Google Scholar
• Mauro MJ. Defining and managing imatinib resistance. Hematol Am Soc Hematol Educ Program. 2006;2006(1):219–225.
   Google Scholar
• Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and bcr-abl in cell cycle progression and leukemogenesis. Leukemia. 2004;18(2):189–218.
   PubMed Web of Science ®Google Scholar
• Deming PB, Schafer ZT, Tashker JS, Potts MB, Deshmukh M, Kornbluth S. BCR-ABL-mediated protection from apoptosis downstream of mitochondrial cytochrome c release. Mol Cell Biol. 2004;24(23):10289–10299.
   PubMed Web of Science ®Google Scholar
• Hantschel O, Superti-Furga G. Regulation of the c-ABL and BCR-ABL tyrosine kinases. Nat Rev Mol Cell Biol. 2004;5(1):33–44.
   PubMed Web of Science ®Google Scholar
• Whang YE, Tran C, Henderson C, Syljuasen RG, Rozengurt N, McBride WH, Sawyers CL. c-ABL is required for development and optimal cell proliferation in the context of p53 deficiency. Proc Natl Acad Sci U S A. 2000;97(10):5486–5491.
   PubMed Web of Science ®Google Scholar
• Jonuleit T, Peschel C, Schwab R, van der Kuip H, Buchdunger E, Fischer T, Huber C, Aulitzky WE. BCR-ABL kinase promotes cell cycle entry of primary myeloid cml cells in the absence of growth factors. Br J Haematol. 1998;100(2):295–303.
   PubMed Web of Science ®Google Scholar
• Skorski T. BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene. 2002;21(56):8591–8604.
   PubMed Web of Science ®Google Scholar
• Slupianek A, Hoser G, Majsterek I, Bronisz A, Malecki M, Blasiak J, Fishel R, Skorski T. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of g(2)/m phase, and protection from apoptosis. Mol Cell Biol. 2002;22(12):4189–4201.
   PubMed Web of Science ®Google Scholar
• Jia L, Wang R, Tang DD. Abl regulates smooth muscle cell proliferation by modulating actin dynamics and ERK1/2 activation. Am J Physiol Cell Physiol. 2012;302(7):C1026–1034.
   PubMed Web of Science ®Google Scholar
• Zhang H, Yi J, Yoon D, Ryoo Z, Lee I, Kim M. Imatinib and GNF-5 exhibit an inhibitory effect on growth of hepatocellar carcinoma cells by downregulating s-phase kinase-associated protein 2. J Cancer Prev. 2020;25(4):252–257.
   PubMed Web of Science ®Google Scholar
• Sirvent A, Boureux A, Simon V, Leroy C, Roche S. The tyrosine kinase abl is required for src-transforming activity in mouse fibroblasts and human breast cancer cells. Oncogene. 2007;26(52):7313–7323.
   PubMed Web of Science ®Google Scholar
• Siu KT, Rosner MR, Minella AC. An integrated view of cyclin e function and regulation. Cell Cycle. 2012;11(1):57–64.
   PubMed Web of Science ®Google Scholar
• Gurzov EN, Izquierdo M. Cyclin E1 knockdown induces apoptosis in cancer cells. Neurol Res. 2006;28(5):493–499.
   PubMed Web of Science ®Google Scholar
• Mazumder S, DuPree EL, Almasan A. A dual role of cyclin E in cell proliferation and apoptosis may provide a target for cancer therapy. Curr Cancer Drug Targets. 2004;4(1):65–75.
   PubMed Web of Science ®Google Scholar
• Xu X, Nakano T, Wick S, Dubay M, Brizuela L. Mechanism of CDK2/cyclin E inhibition by p27 and p27 phosphorylation. Biochemistry. 1999;38(27):8713–8722.
   PubMed Web of Science ®Google Scholar
• Tomoda K, Kato JY, Tatsumi E, Takahashi T, Matsuo Y, Yoneda-Kato N. The JAB1/COP9 signalosome subcomplex is a downstream mediator of BCR-ABL kinase activity and facilitates cell-cycle progression. Blood. 2005;105(2):775–783.
   PubMed Web of Science ®Google Scholar
• Mrozek-Wilczkiewicz A, Malarz K, Rams-Baron M, Serda M, Bauer D, Montforts FP, Ratuszna A, Burley T, Polanski J, Musiol R. Iron chelators and exogenic photosensitizers. Synergy through oxidative stress gene expression. J Cancer. 2017;8(11):1979–1987.
   PubMed Web of Science ®Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Res. 2010;70(2):440–446.
   PubMed Web of Science ®Google Scholar
• Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621–681.
   PubMed Web of Science ®Google Scholar